NEWSWIRETODAY Press Release & Newswire Distribution | HOME
MOST TRUSTED NEWSWIRE PRESS RELEASE DISTRIBUTION
PRTODAY / NewswireToday press release distribution service network
Agency / Source: Biotrial

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Biotrial’s ECG Central Laboratory Selected by Mortara As Certified Partner - Biotrial, a leading CRO for early phase clinical trials, and its core ECG Central Laboratory announced today that it has achieved Mortara Certified Partner status - Biotrial.com
Biotrial’s ECG Central Laboratory Selected by Mortara As Certified Partner

 

NewswireTODAY - /newswire/ - Rennes, Ille-et-Vilaine, France, 2009/06/09 - Biotrial, a leading CRO for early phase clinical trials, and its core ECG Central Laboratory announced today that it has achieved Mortara Certified Partner status - Biotrial.com.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Biotrial, a leading Contract Research Organization in early development and recognized expert in QT studies, proposes through its ECG Central Laboratory division an integrated solution for collecting, managing and analyzing cardiac safety data collected in-house or externally. Biotrial also provides study design consulting, statistical analysis and reports.

Biotrial’s ECG Central Laboratory’s IFA Commitment is: Integrity of data delivered, Flexibility to sponsor’s needs and Adaptability to the ever changing technological and regulatory environment.
“Mortara is happy to welcome Biotrial as a certified partner.” said Mark Mentzer, VP Clinical Research at Mortara. This new certification makes Biotrial one of only a few partners worldwide recognized by Mortara for rigorously adhering to the HL7 annotated ECG standard used by the FDA to manage its data warehouse. This certification enhances the company’s capability to deliver cardiovascular data which follows the strict international requirements for annotated ECGs. It is another guarantee for sponsors that the ECG data processed by Biotrial is fully compliant when submitted for regulatory review.

Jean-Marc Gandon, Biotrial CEO, commented: “Over the years Biotrial has proved its excellence in performing clinical studies; with this certification we are also demonstrating it with our ECG Central Laboratory services. Our main goal is to accompany our clients in their product development and to constantly ensure compliance with international regulations and expectations.”
“Adaptability to ever changing technological and regulatory environments is in our motto,” said Philippe l’Hostis, Head of Biotrial ECG Central Laboratory. “This new certification illustrates how we constantly strive to improve the quality of our processes at every level from ECG acquisition to submission, allowing us to strengthen Biotrial’s position as a key provider for Thorough QT studies.”

About Mortara Instrument
Based in Milwaukee, WI, Mortara Instrument, Inc. is distinguished in the field of noninvasive cardiology for innovations that are the core of the company’s complete line of ECG products including electrocardiographs, stress exercise systems, Holter systems, data warehousing solutions, and cardiology monitoring systems.

About Biotrial
Founded in 1989 by Jean-Marc Gandon, PharmD, (President & CEO), Biotrial (biotrial.com) is an independent and privately owned CRO.
With 150 beds and a staff of 250 in several subsidiaries in France and the UK, Biotrial runs over 80 studies per year, either in their own clinics in Paris and Rennes, or in cooperation with hospital specialists and general practitioners.
With a large range of services from Phase I studies, Clinical Trial Management Phase II-IV, Oncology, Data Management, Biostatistics, Central Labs (ECG, Imaging), Medical Writing, Non-Clinical Pharmacology, QA & advice in Regulatory Affairs, Biotrial can manage every step of your development process.
Since the creation of their ECG and Imaging Central Laboratory, Biotrial expert cardiologists have manually read more than 350 000 ECGs and measured more than one million QT intervals. More than 120 cardiac safety studies have been directly managed in-house or outside since the implementation of digital ECGs.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Biotrial

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick NewswireToday Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Biotrial’s ECG Central Laboratory Selected by Mortara As Certified Partner

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name NewswireToday and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Anne Peron - Biotrial.com 
+33(0)2 99 59 91 91 anne.peron[.]biotrial.com
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Biotrial securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Articles From Biotrial / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Newswires:

Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions
Ipsen Expands Early Development Pipeline with Simcere Zaiming’s Innovative Antibody Drug Conjugate
Ipsen Update on Phase II FALKON Trial in Patients with Ultra-rare Bone Disease, Fibrodysplasia Ossificans Progressiva (FOP)
Ipsen Completes Acquisition of ImCheck Therapeutics, Expanding Oncology Pipeline
NEC Presents Phase I Results for Personalized AI-Powered Oral Cancer Vaccine NECVAX-NEO1 at ESMO Immuno-Oncology Congress 2025
Ono Announces Oral Presentation of Positive Topline Results from Phase 2a Study of Sapablursen in Polycythemia Vera

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
NewswireToday Celebrates 10 Years in Business


PREMIUM Members


Visit  BizJobs.com

Visit  La Bella Bakery Artisan Bakery Arizona





 
  ©2005-2026 NewswireToday — Limelon Advertising, Co.
Home | About | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneurs newswire distribution prtoday.com newswiredistribution asianewstoday bizwiretoday USA pr UK today - NOT affiliated with PRNewswire as we declined their partnership offer in 2013
 
PRTODAY & NewswireTODAY are NOT affiliated with USA TODAY (usatoday.com)